# Bugworks Research India Pvt.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bugworks-research-india-pvt

- Industry: Biotechnology
- Headquarters: Bangalore, India
- Website: www.bugworksresearch.com
- Total disclosed funding: $34M
- Latest round: Series B (Feb 9, 2022)
- Investors on record: 6

## About

Bugworks Research India Pvt. Ltd. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting antimicrobial resistance and cancer, focusing on advanced small molecule therapeutics.Founded in 2014 and headquartered in Bangalore, India, Bugworks Research India Pvt. Ltd. specializes in creating therapies for antimicrobial resistance and cancer. The company has secured funding through a SERIES B round, raising USD 18.00 mn in February 2022, led by Lightrock, with participation from multiple investors. Anand Anandkumar, who also serves as CEO, has played a key role in the company's development and growth.Bugworks offers a range of innovative small molecule therapeutics aimed at battling antimicrobial resistance and treating various cancers. Their antibacterial solutions are designed to tackle numerous severe infections caused by both Gram-Negative and Gram-Positive microbes, while their oncology treatments focus on addressing the challenges of difficult-to-treat solid tumors. The company primarily markets its products in regions with significant unmet medical needs, notably in the United States and Europe.In the most recent fiscal year of 2023, Bugworks recorded revenue of USD 3,453,542.90 and an EBITDA of USD 492,152.90, deriving income primarily through collaborations and partnerships with established biopharmaceutical firms.Bugworks intends to leverage the USD 18.00 mn raised in the SERIES B funding round to advance the clinical development of their lead candidate, BWC0977, as well as the preclinical development of an adenosine immuno-oncology agent. The company aims to launch new products targeting antimicrobial resistance and cancer treatment by expanding their research initiatives. Additionally, Bugworks is focused on entering new geographic markets where unmet medical needs exist, to enhance their outreach and impact in the healthcare industry.

## Funding rounds

- Series B, Feb 9, 2022, $18M — University of Tokyo Edge Capital Partners, Global Brain, Lightrock, Acquipharma, 3one4Capital Advisors, Featherlite, Inc.
- Series B, Apr 22, 2020, $7.5M — University of Tokyo Edge Capital Partners, Global Brain, Acquipharma, 3one4Capital Advisors
- Series A, Aug 13, 2018, $9M — University of Tokyo Edge Capital Partners, Acquipharma, 3one4Capital Advisors

## Investors

- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series A, Series B
- Acquipharma — Series A, Series B
- 3one4Capital Advisors (https://capitalatlas.ai/funds/3one4capital-advisors) — Series A, Series B
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series B
- Lightrock (https://capitalatlas.ai/funds/lightrock) — Series B
- Featherlite, Inc. — Series B